Evonik stock trades near EUR 17.47 after analyst cuts

Published on 09/21/2026 at 18:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock traded at EUR 17.47 on September 21, 2026, up 0.9 percent from the prior close. Investing.com also cited a 52-week range of EUR 12.49 to EUR 19.21 and a market value of EUR 8.1 billion.

Fotorealistisches Luftbild eines Spezialchemiewerks mit Destillationstürmen bei Sonnenuntergang — Evonik Industries DE000EVNK013 zeigt ein fotorealistisches Luftbild eines großen Spezialchemiewerks bei Abenddämmerung, Illustration mit AI erstellt.

Evonik stock (ISIN DE000EVNK013) traded at EUR 17.47 on September 21, 2026, up 0.9 percent from the prior close of EUR 17.31. Investing.com also put the 52-week range at EUR 12.49 to EUR 19.21 and market capitalization at EUR 8.1 billion.

Analysts stayed cautious

According to Investing.com on September 21, 2026, Morgan Stanley cut Evonik to Equal-weight from Overweight and lowered its target to EUR 18 from EUR 21, while JPMorgan kept a Sell rating from September 11. The same overview listed Citi at Buy with a target of EUR 22 on September 2 and Berenberg at Sell with EUR 15.50 on August 10.

That leaves a narrow gap to the market price. The Investing.com consensus table showed an average target of EUR 18.05 across 12 analysts, only EUR 0.58 above the cited price.

Half-year numbers

Investing.com said Evonik's first-half 2026 revenue fell 5.4 percent to EUR 7.25 billion, and adjusted EBITDA margin slipped to 9.7 percent. The same report said the half-year figures were published on August 1, 2026.

The comparison is clear: a 5.4 percent drop in revenue and a margin below 10 percent explain why the stock still trades well below its 52-week high of EUR 19.21. For investors, the margin is the more important number.

Stock level

At EUR 17.47 on September 21, 2026, Evonik stock sits 9.1 percent below the 52-week high and 39.7 percent above the 52-week low of EUR 12.49. The quoted market value of EUR 8.1 billion shows a mid-cap valuation that is still being judged against weak half-year profitability.